Alamar Biosciences, a protein detection and analysis life sciences company, aims to raise up to $159 million in its IPO.
Why it matters: Alamar's debut could help set the tone for biotech and life sciences IPOs for the rest of Q2, after earlier listings delivered mixed results.
